Contents

Search

HOPE & HOPE Too trials

Diabetes subgroup: Primary outcomes: - cardiovascular death, myocardial infarction, stroke, heart failure, end-stage renal disease Results: - high risk patients given a) 10 mg of ramipril/day had lower incidence of cardiovascular events b) 1.25 mg of rampril/day of no benefit Vitamin E subgroup: [3] Vitamin E 400 IU/day mean follow-up of 7 years Results: 1) no differences in beween vit E & placebo in: - cancer incidence, cancer deaths - combined endpoint of myocardial infarction, stroke, cardiovascular death (21.5% vs 20.6%) 2) higher risk of heart failure with vit E vs placebo (13.5% vs 12.1%)

Related

Heart Outcomes Prevention Evaluation (HOPE)

General

clinical trial

References

  1. Journal Watch 24(8):62, 2004 Marre M et al, BMJ 328:495,2004 PMID: 14960504 http://bmj.bmjjournals.com/cgi/content/full/328/7438/495
  2. Journal Watch 20(5):37, 2000 Lancet 355:253, 2000
  3. Journal Watch 25(8):61, 2005 Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005 Mar 16;293(11):1338-47. PMID: 15769967